PCSK9 and type 2 diabetes mellitus: Several consensus statements and lipid guidelines state it may be reasonable to consider therapy with PCSK9 inhibitors in individuals with atherosclerotic cardiovascular disease and/or T2DM (with target organ damage or with a major cardiovascular risk factor) who are not adequately treated with maximally tolerated statin therapy (3, 9, 10, 23).